Go to the list of all blogs
Allana's Avatar
published in Blogs
Jun 25, 2026
Why Is Aquestive Therapeutics (AQST) Stock Down -14% Today?

Why Is Aquestive Therapeutics (AQST) Stock Down -14% Today?

Key Takeaways

  • AQST shares fell sharply by 14.33% in early trading on elevated volume.
  • No single company-specific catalyst was immediately apparent for the decline.
  • The move occurred amid broader weakness in small-cap biotech and specialty pharma names.
  • Recent company developments, including Q1 results and debt refinancing, had previously supported the stock.
  • Traders are monitoring upcoming regulatory updates for Anaphylm and the next earnings release scheduled for August.

Opening Summary

Aquestive Therapeutics, Inc. develops and commercializes innovative pharmaceutical products using its proprietary PharmFilm technology, focusing on central nervous system disorders and other therapeutic areas. On June 25, 2026, with the market open, AQST shares traded at $4.2750, down 14.33% from the prior session's close of $4.9900. The decline reflects selling pressure without an immediate identifiable news trigger, as the stock pulled back from recent gains.

Market Reaction and Volume

Trading volume exceeded the average, indicating heightened investor activity. The selloff aligned with softer sentiment across select small-cap healthcare peers, though major indices showed mixed performance. Technical levels near recent support were tested as the price moved lower intraday.

Broader Sector and Market Context

The drop took place against a backdrop of variable performance in the specialty pharmaceuticals sector. While AQST had benefited earlier from positive clinical and financing updates, today's action appeared driven more by profit-taking and general risk-off flows in smaller biotech and pharma names rather than any fundamental shift in the company's outlook.

Trending AI Robots

Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with only the top performers featured in this curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade. Investors seeking automated trading insights can explore the platform for additional tools and strategies.

What Comes Next for AQST

Investors will watch for regulatory progress on the Anaphylm sublingual film NDA resubmission targeted for the third quarter. The company is also expected to report second-quarter results around August 11. Key risks include clinical development timelines, regulatory decisions, and ongoing cash burn typical of development-stage biopharma firms. Market participants will continue to assess sector sentiment and any new corporate announcements.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AQST

AQST's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The 10-day RSI Indicator for AQST moved out of overbought territory on June 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on June 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

AQST moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AQST crossed bearishly below the 50-day moving average on July 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AQST broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AQST entered a downward trend on July 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (46.269). P/E Ratio (0.000) is within average values for comparable stocks, (100.083). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.733). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (8.326) is also within normal values, averaging (116.105).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AQST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.01B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 12%. CPHI experienced the highest price growth at 38%, while SXTC experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 195%. For the same stocks of the Industry, the average monthly volume growth was 93% and the average quarterly volume growth was 111%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
AQST
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer thin film pharmaceutical and over the counter drug products

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Major
Address
30 Technology Drive
Phone
+1 908 941-1900
Employees
147
Web
https://www.aquestive.com
Interact to see
Advertisement
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
Prologis (PLD), the world’s largest logistics-focused REIT, reported fourth-quarter and full-year 2025 earnings on January 21, 2026, capping a standout year for the industrial real estate sector. Demand for modern logistics facilities remains elevated as e-commerce expansion and supply chain reconfiguration continue to reshape global distribution networks.
The Travelers Companies, Inc.(TRV), a major player in the property and casualty insurance market, reported fourth-quarter 2025 results on January 21, 2026, closing out a year marked by underwriting discipline despite volatile weather activity and pricing pressures. The results underscore Travelers’ ability to generate strong profitability while navigating challenges in personal insurance lines and heightened catastrophe risk.
FingerMotion, Inc. (NASDAQ: FNGR) reported fiscal third-quarter 2026 results on January 15, 2026, triggering a sharp selloff as investors reacted to a steep revenue decline and widening losses. Shares fell roughly 32% following the release after the mobile services provider disclosed a 32% year-over-year drop in revenue and a net loss of $1.67 million for the quarter ended November 30, 2025.
CSX Corporation, a major U.S. East Coast rail operator, reports fourth-quarter 2025 earnings after market close today, marking the end of a year characterized by uneven freight recovery. Comparing CSX with Canadian Pacific Kansas City (CP), now a transcontinental operator following its 2023 merger, highlights contrasting strategies within the North American rail sector.
Procter & Gamble (PG) reports fiscal Q2 2026 earnings on January 22, with consensus expecting modest revenue growth amid commodity and tariff pressures. EPS is forecast at ~$1.87, slightly below last year’s $1.88. Colgate-Palmolive (CL) is set to release Q4 2025 earnings on January 30, while Unilever (UL) reports full-year 2025 results on February 12.
CSX (NASDAQ: CSX) reports Q4 2025 earnings after market close on January 22, 2026, with consensus EPS ~$0.42 and revenue ~$3.57 billion. Union Pacific (NYSE: UNP) follows on January 27, with EPS expected near $2.89 and revenue around $6.15 billion. Norfolk Southern (NYSE: NSC) closes the week on January 29, with consensus EPS ~$2.77.
The SPDR S&P Aerospace & Defense ETF (XAR) has surged to a new 52-week high above $281 this week, climbing 21% month-to-date and 20% year-to-date through January 2026. The rally, driven by robust sector momentum and a clean technical breakout, is outpacing broader indices like the S&P 500. XAR’s equal-weighted structure amplifies gains from top aerospace and defense holdings in missiles, aircraft, and space systems, attracting significant trader and institutional attention amid heightened geopolitical tensions.
The iShares U.S. Aerospace & Defense ETF (ITA) continues to attract trader attention, building on a remarkable 47.7% gain in 2025 amid rising defense budgets and heightened global security concerns. The ETF is approaching all-time highs, with top holdings such as GE Aerospace and RTX Corporation driving the rally. Traders are adding positions on dips while monitoring confirmation above key resistance levels near recent peaks, anticipating a potential technical breakout.
ProShares Ultra Gold (UGL), the leveraged ETF designed to deliver 2× the daily performance of gold futures, has climbed sharply this week as gold prices continue near historic levels. The ETF’s move reflects renewed inflows into gold-related products and heightened investor interest in safe-haven assets amid ongoing geopolitical and macroeconomic uncertainty. UGL’s price action closely mirrors the strong trend in gold futures, attracting short-term momentum trading even as the leveraged structure carries heightened risk.
Hubbell Incorporated (HUBB) reached an all-time high of $485.91 this week, reflecting strong buying interest in the industrial sector. The breakout comes amid mixed institutional activity—some funds trimming positions while others add new stakes—highlighting investor focus on HUBB’s multi-year rally.
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.